Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could help track rare Cancer's response to treatment

NCT ID NCT06521775

Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study tested whether a special PET/CT scan using a radioactive tracer called Ga-68 PSMA-11 can detect treatment response in patients with metastatic adenoid cystic carcinoma, a rare salivary gland cancer. Six adults with this cancer underwent the scan at two time points. The goal was to see if the imaging could help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ga-68 PSMA-11 (radioactive imaging agent)
What this could lead to
If successful, this imaging method could help doctors better track how well treatments are working in patients with this rare cancer.
What could go wrong
This is a very small pilot study (6 participants) focused on imaging, not treatment. It may not lead to changes in care or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

6 people

The number who actually took part.

Started

Aug 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age * Diagnosis of metastatic adenoid cystic carcinoma * Enrolled in protocol MC200708 * Ability to tolerate a Ga68 PSMA PET/CT imaging study * Willingness to return for a second PSMA PET/CT scan in approximately 12-20 weeks from the baseline PET/CT * Ability to give appropriate consent or have an appropriate representative available to do so Exclusion Criteria: * Unable to undergo PET/CT scan * Not a participant in MC200708 * \< 18 years of age * Persons who are pregnant or nursing * Persons unable to consent to the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic adenoid cystic carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma metastatic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic adenoid cystic carcinoma

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.